S. Mpofu

发表

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

A. Gottlieb, P. Rahman, B. Kirkham, 2017, Rheumatology.

Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study

D. M. van der Heijde, R. Landewé, P. Rahman, 2021, RMD Open.

Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study

L. Coates, B. Kirkham, P. Mease, 2018, Arthritis care & research.

There is a risk of overtreatment when the Disease Activity Score in 28 joints is based solely on subjective parameters . A cross-sectional , exploratory , DANBIO study

P. Conaghan, L. Laasonen, A. Kavanaugh, 2016 .

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

A. Gottlieb, P. Mease, I. McInnes, 2020, The Lancet.

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

D. M. van der Heijde, R. Landewé, P. Mease, 2016, Arthritis & rheumatology.

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

M. Genovese, P. Durez, Sang-Heon Lee, 2014, The Journal of Rheumatology.

Secukinumab for Long‐Term Treatment of Psoriatic Arthritis: A Two‐Year Followup From a Phase III, Randomized, Double‐Blind Placebo‐Controlled Study

P. Geusens, A. Reimold, P. Mease, 2017, Arthritis care & research.

THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)

S. Kandala, I. McInnes, A. Kavanaugh, 2015 .

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

R. Landewé, P. Rahman, D. Heijde, 2015 .

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

D. M. van der Heijde, R. Landewé, P. Rahman, 2015, The New England journal of medicine.

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

A. Gottlieb, P. Rahman, D. Heijde, 2015, The Lancet.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

M. Dougados, P. Emery, A. Deodhar, 2015, The New England journal of medicine.

Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

Piet Geusens, Philip J Mease, Luminita Pricop, 2018, RMD Open.

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study

D. M. van der Heijde, R. Landewé, P. Rahman, 2018, Annals of the rheumatic diseases.

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study

P. Mease, I. McInnes, A. Kavanaugh, 2016, The Journal of Rheumatology.

Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study

P. Emery, A. Deodhar, D. Baeten, 2016, Annals of the rheumatic diseases.

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

P. Rahman, P. Mease, I. McInnes, 2018, Arthritis Research & Therapy.

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Patrick Durez, M. Genovese, V. Mazurov, 2012, Annals of the rheumatic diseases.

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)

V. Strand, P. Mease, L. Gossec, 2016, Annals of the rheumatic diseases.

Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies

A. Deodhar, L. Gensler, A. Winseck, 2021, The Journal of Rheumatology.

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results from the Phase 3 FUTURE 1 Study

P. Geusens, A. Reimold, P. Mease, 2019, ACR open rheumatology.

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis : 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.

P. Rahman, P. Conaghan, P. Mease, 2014 .

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

P. Mease, I. McInnes, H. Thom, 2018, Rheumatology and Therapy.

Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial

A. Gottlieb, P. Rahman, B. Kirkham, 2014 .

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5

D. M. van der Heijde, R. Landewé, P. Rahman, 2019, Rheumatology.

THU0448 Secukinumab for The Treatment of Psoriatic Arthritis: Comparative Effectiveness Results versus Adalimumab Up To 48 Weeks Using A Matching-Adjusted Indirect Comparison

P. Mease, I. McInnes, H. Thom, 2016 .

Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.

A. Gottlieb, A. Blauvelt, B. Sigurgeirsson, 2015, Journal of drugs in dermatology : JDD.

SAT0579 Secukinumab Safety and Tolerability in Patients with Active Psoriatic Arthritis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials (Future 1 and Future 2)

P. Mease, I. McInnes, H. Richards, 2015 .

THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1)

D. M. van der Heijde, R. Landewé, P. Mease, 2015 .

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

P. Geusens, A. Reimold, P. Mease, 2018, RMD Open.

Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

A. Gnanasakthy, M. Kosinski, V. Strand, 2014, Health and Quality of Life Outcomes.

THU0442 Reduction in Fatigue in Patients with Active Psoriatic Arthritis Are Sustained over 2 Years: Long-Term Results of Two Phase 3 Studies with Secukinumab

P. Conaghan, L. Gossec, M. Østergaard, 2016 .

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

P. Mease, S. Jugl, S. Mpofu, 2018 .

Applying Item Response Theory Methods to Improve the Measurement of Fatigue in a Clinical Trial of Rheumatoid Arthritis Patients Treated with Secukinumab

A. Gnanasakthy, M. Kosinski, J. Bjorner, 2013 .